Hypogonadism is a medical condition where the body produces insufficient testosterone, affecting approximately many men over age 60 and 1-3% of younger men. The condition occurs when the testes fail to produce adequate levels of testosterone (primary hypogonadism) or when the brain fails to signal proper hormone production (secondary hypogonadism). Normal testosterone levels range from 300-1,000 ng/dL, with hypogonadism typically diagnosed when levels fall below 300 ng/dL accompanied by clinical symptoms. Primary symptoms include reduced libido, erectile dysfunction, fatigue, decreased muscle mass, and mood changes. Secondary hypogonadism often results from pituitary dysfunction, obesity, or certain medications. Diagnosis requires both low testosterone blood tests and symptomatic presentation. Treatment options in 2026 include testosterone replacement therapy, lifestyle modifications, and emerging peptide therapy approaches that can stimulate natural hormone production.
Key Takeaways
- Hypogonadism affects 20% of men over 60, with testosterone levels below 300 ng/dL
- Primary type involves testicular dysfunction; secondary type involves brain-hormone signaling problems
- Common symptoms include low libido, fatigue, muscle loss, and mood changes
- Diagnosis requires blood tests showing low testosterone plus clinical symptoms
- Treatment options include testosterone replacement therapy and peptide interventions
Types and Causes of Hypogonadism
Primary hypogonadism results from direct testicular dysfunction, affecting approximately 60% of hypogonadal men. Common causes include Klinefelter syndrome (affecting 1 in 500-1,000 men), testicular injury, chemotherapy, radiation, or infections like mumps orchitis. The testes cannot produce adequate testosterone despite normal signals from the brain. Secondary hypogonadism accounts for the remaining 40% of cases and stems from hypothalamic-pituitary dysfunction. Causes include pituitary tumors, head trauma, chronic opioid use (reducing testosterone by 50-the vast majority), obesity (decreasing levels by 30% in severely obese men), and aging. Type 2 diabetes doubles the risk of developing secondary hypogonadism compared to healthy men.Symptoms and Clinical Presentation
Sexual symptoms appear first in most men, with 85% experiencing decreased libido and 70% reporting erectile dysfunction when testosterone drops below 250 ng/dL. Physical changes develop gradually and include reduced muscle mass (3-5% annually), increased body fat (particularly abdominal), decreased bone density, and reduced body hair growth. Cognitive and emotional symptoms affect quality of life significantly. Men report decreased energy levels, difficulty concentrating, irritability, and depression. Sleep disturbances occur in 60% of hypogonadal men. These symptoms often overlap with normal aging, making diagnosis challenging without proper testing.Diagnosis and Testing
Accurate diagnosis requires morning testosterone measurements taken between 7-10 AM when levels peak naturally. Healthcare providers typically order two separate tests to confirm low levels, as testosterone fluctuates daily. Total testosterone below 300 ng/dL combined with symptoms indicates hypogonadism, though some men experience symptoms with levels between 300-400 ng/dL. Additional tests include luteinizing hormone (LH) and follicle-stimulating hormone (FSH) to distinguish primary from secondary hypogonadism. Elevated LH and FSH suggest primary hypogonadism, while low or normal levels indicate secondary dysfunction. Prolactin, thyroid function, and complete blood counts help identify underlying causes.Treatment Options and Management
Testosterone replacement therapy remains the primary treatment, available as gels, injections, patches, or pellets. Treatment typically raises testosterone levels to 400-700 ng/dL, improving symptoms in 70-80% of men within 3-6 months. Regular monitoring prevents potential side effects like elevated red blood cell counts or prostate issues. Sermorelin and Ipamorelin offer alternative approaches for men with secondary hypogonadism by stimulating natural hormone production. These peptides can increase growth hormone levels by 200-400%, potentially supporting testosterone production. BPC-157 and TB-500 may provide additional benefits for tissue repair and recovery during hormone optimization. As of 2026, these peptide therapies cost approximately $200-500 monthly through telehealth providers.Frequently Asked Questions
What testosterone level is considered hypogonadism?
Hypogonadism is typically diagnosed when total testosterone levels fall below 300 ng/dL (10.4 nmol/L) on two separate morning measurements, combined with clinical symptoms. However, some men experience symptoms with levels between 300-400 ng/dL. Normal ranges vary by laboratory but generally span 300-1,000 ng/dL. Age-related decline of 1-2% annually after age 30 is normal, but symptomatic drops below 300 ng/dL warrant medical evaluation.
Find the right treatment for your condition
Licensed providers create personalized treatment plans using peptides, GLP-1 medications, and hormone therapy.
Start Free Assessment →Can hypogonadism be reversed naturally?
Secondary hypogonadism may improve with lifestyle modifications, weight loss, and addressing underlying causes. Men who lose 15-20% of body weight can increase testosterone levels by 200-300 ng/dL. Discontinuing certain medications, treating sleep apnea, and reducing alcohol intake can restore function. Primary hypogonadism typically requires hormone replacement therapy, as testicular damage is usually permanent. Regular exercise, adequate sleep, and stress management support healthy testosterone levels.
What are the long-term effects of untreated hypogonadism?
Untreated hypogonadism increases risks of osteoporosis, with bone density decreasing 2-3% annually, cardiovascular disease, metabolic syndrome, and type 2 diabetes. Men experience progressive muscle loss, increased body fat, and potential cognitive decline. Depression affects 25-30% of untreated hypogonadal men. Sexual dysfunction worsens over time, impacting relationships and quality of life. Early treatment prevents most complications and improves long-term health outcomes significantly.
How long does testosterone replacement therapy take to work?
Sexual symptoms typically improve within 2-6 weeks, with libido and erectile function showing early response. Energy levels and mood changes become apparent within 3-6 weeks. Muscle mass and strength improvements require 12-16 weeks of consistent treatment. Bone density changes take 6-12 months to become measurable. Maximum benefits usually occur within 6 months of optimal dosing. Individual responses vary, and some men notice improvements within the first week of treatment.
Sources
- Bhasin S, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID: 29562364
- Corona G, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytical study. Eur J Endocrinol. 2011;165(5):687-701. PMID: 21852391
- Wu FC, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123-135. PMID: 20554979
- Dandona P, et al. Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab. 2011;96(9):2643-2651. PMID: 21896895
- Snyder PJ, et al. Effects of testosterone treatment in older men. N Engl J Med. 2016;374(7):611-624. PMID: 26886521
- Mulhall JP, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423-432. PMID: 29601923
- Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol. 2009;5(12):673-681. PMID: 19859074
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →